17
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Possible Digenic Disease in a Caucasian Family with COL4A3 and COL4A5 Mutations

      case-report

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Microscopic hematuria is a common feature of patients with Alport syndrome, a familial nephropathy due to mutations in COL4A3, COL4A4 or COL4A5. These genes encode for α3, α4, and α5 type IV collagen polypeptide chains (collagen IV α345), crucial for the structural component of the glomerular basement membrane. Even patients with mild phenotype, namely isolated microhematuria (X-linked females with thin basement membrane on electron microscopy or heterozygous carriers of COL4A3 or COL4A4 mutations), can potentially progress to proteinuria and to end-stage renal disease. Recent pedigree analyses provided evidence for digenic inheritance of Alport syndrome by concomitant mutations in  COL4A3/ COL4A4 or COL4A4/ COL4A5. We describe a Caucasian family with concomitant COL4A3 and COL4A5 mutations, consisting of a novel c.4484A>G COL4A3 (p.Gln1495Arg) mutation and a previously reported c.1871G>A COL4A5 (p.Gly624Asp) mutation. Our segregation analysis raises the possibility that Alport syndrome resembles also digenic inheritance by COL4A3/ COL4A5.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          2019
          March 2019
          18 January 2019
          : 141
          : 3
          : 213-218
          Affiliations
          [_a] aDepartment of Nephrology and Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany
          [_b] bExperimental and Clinical Research Center (ECRC), a Cooperation between the Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine, Berlin, Germany
          Author notes
          *Mira Choi, Universitätsmedizin Charité, Augustenburger Platz 1, DE–13353, Berlin (Germany), E-Mail mira.choi@charite.de
          Article
          495764 Nephron 2019;141:213–218
          10.1159/000495764
          30661074
          f1235e4a-f77c-4f27-9bc0-29283910ac18
          © 2019 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 17 July 2018
          : 26 November 2018
          Page count
          Figures: 2, Pages: 6
          Categories
          Experimental Nephrology and Genetics: Case Study of Genetic Interest

          Cardiovascular Medicine,Nephrology
          COL4A3 , COL4A5 ,Alport syndrome,Digenic inheritance , Familial hematuria,Genetic diseases,Thin basement membrane

          Comments

          Comment on this article